Abatacept in the treatment of psoriatic arthritis: Biological and clinical profiles of the responders

Gaetano Zizzo, Elisa Gremese, Gianfranco Ferraccioli

Research output: Contribution to journalReview articlepeer-review

Abstract

Abatacept (CTLA4Ig), a selective T-cell costimulation modulator, has been approved for the treatment of psoriatic arthritis patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs, but not for those with uncontrolled skin lesions, nor with axial involvement. In this review, we will try to interpret such a differential efficacy of abatacept on the psoriatic arthritis clinical domains, on the basis of its differential effectiveness on the diverse T-cell subsets at different sites. Clinical and biological profiles of possible responders to abatacept will be provided.

Original languageEnglish
Pages (from-to)807-821
Number of pages15
JournalImmunotherapy
Volume10
Issue number9
DOIs
Publication statusPublished - Jul 1 2018

Keywords

  • abatacept
  • CD28
  • CTLA-4
  • CTLA4Ig
  • enthesitis
  • obesity
  • psoriasis
  • psoriatic arthritis
  • T cells
  • therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Abatacept in the treatment of psoriatic arthritis: Biological and clinical profiles of the responders'. Together they form a unique fingerprint.

Cite this